Literature DB >> 15562032

Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures.

N Caraccio1, R Giannini, S Cuccato, P Faviana, P Berti, D Galleri, A Dardano, F Basolo, E Ferrannini, F Monzani.   

Abstract

We evaluated in primary human thyrocyte cultures the effect of interferon (IFN)-alpha and -beta on the expression of thyroid peroxidase (TPO), sodium/iodide symporter (NIS), and thyroglobulin (Tg) as well as T(4) release. Human thyrocyte cultures were carried out with fresh normal thyroid tissue. Gene and protein expression of Tg, TPO, and NIS were assessed by RT-PCR and Western blot analysis after 24, 48, and 72 h of treatment with TSH alone (10 mIU/ml) and in combination with IFN alpha or -beta (10(4) U/ml). IFN inhibited the TSH-stimulated gene expression of Tg, TPO, and NIS in a time-dependent manner without significant differences between IFN alpha and -beta. Moreover, the addition of both type I IFNs clearly reduced the TSH-stimulated protein expression of Tg, TPO, and NIS after 72 h of exposure. Finally, this down-regulation was associated with a reduction of T(4) release by almost 50%. In conclusion, our study shows that both IFN alpha and -beta down-regulate the TSH-stimulated expression of Tg, TPO, and NIS as well as T(4) release. Indeed, the development of hypothyroidism during type I IFN therapy may be related, at least in part, to an abnormal expression and function of key proteins involved in iodine uptake and organification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562032     DOI: 10.1210/jc.2004-1173

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

Review 2.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

3.  Elevated follicular helper T cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of Graves' disease.

Authors:  Jin Zhang; Meng Ren; Hua Zeng; Ying Guo; Zhenwu Zhuang; Zhimei Feng; Haiyan Yan; Mingtong Xu; Weiwen Liang; Chuan Yang; Hua Cheng; Helin Ding; Li Yan
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

Review 4.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

5.  N-acetylcysteine and 15 deoxy-{delta}12,14-prostaglandin J2 exert a protective effect against autoimmune thyroid destruction in vivo but not against interleukin-1{alpha}/interferon {gamma}-induced inhibitory effects in thyrocytes in vitro.

Authors:  Sylvie Poncin; Ides M Colin; Brigitte Decallonne; Isabelle Clinckspooor; Marie-Christine Many; Jean-François Denef; Anne-Catherine Gérard
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

6.  Runt-related transcription factor 3: single nucleotide polymorphism rs760805, gene expression, and methylation status in Helicobacter pylori -infected patients for determination of gastric cancer risk.

Authors:  Nithya Nadarajan; Lakshman Kumar Balasubramanian; Suresh Kuppannan; Chandirasekar Ramachandran; Venkatakrishnan Leelakrishnan
Journal:  J Gastrointest Cancer       Date:  2013-12

Review 7.  Environmental triggers of thyroiditis: hepatitis C and interferon-α.

Authors:  F Menconi; A Hasham; Y Tomer
Journal:  J Endocrinol Invest       Date:  2010-02-28       Impact factor: 4.256

Review 8.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 9.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

10.  A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer.

Authors:  Athanassios Argiris; Sanjiv S Agarwala; Michalis V Karamouzis; Lynn A Burmeister; Sally E Carty
Journal:  Invest New Drugs       Date:  2007-10-02       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.